{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:06:24Z","timestamp":1779696384173,"version":"3.53.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Risperidone is approved for the treatment of serious behavioral problems in children with autism spectrum disorder (ASD). This study examined the effects of risperidone on cardiac conduction in children with ASD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Data were collected from an 8-week, five-site trial conducted by the Research Units on Pediatric Psychopharmacology Autism Network. Children (age 5\u201317 years) were randomly assigned to risperidone (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200949) or placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200952) under double-blind conditions. Risperidone was superior to placebo in reducing serious behavioral problems. A standard 12-lead, electrocardiogram (ECG) was obtained in most subjects at screening and week 8. A pediatric electrophysiologist blind to treatment assignment reviewed all available ECGs for readability, abnormalities, and cardiac conduction parameters, including QTc. The electrophysiologist measurements were compared to machine readings. A second blinded electrophysiologist examined all available ECGs for abnormalities and a 20% random sample for QTc.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 101 randomized subjects in the trial, complete pretreatment and week 8 data were available on 65 subjects (placebo\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200930; risperidone\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200935). The electrophysiologist did not identify any cardiac conduction adverse effects of risperidone and there was no difference in mean change on the QTc compared to placebo. The Bland\u2013Altman plot showed a systematic bias in QTc measurements by the electrophysiologist and machine. Machine readings produced higher values than the electrophysiologist for shorter QTc intervals and machine scoring was lower than electrophysiologist readings for longer QTc values (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001). Two electrophysiologists had overall percent agreements of 82.9% (95% CI: 76.3 to 89.6) on qualitative assessment and 88.6% (95% CI: 79.3 to 98.0) on QTc interval.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Using conventional doses during acute treatment in children with ASD and serious behavioral problems, there was no difference in the mean change in QTc between risperidone and placebo. Compared to the electrophysiologist, the machine readings may miss elevated QTc measurements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2016.0090","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T16:12:50Z","timestamp":1476202370000},"page":"900-908","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder"],"prefix":"10.1177","volume":"26","author":[{"given":"Lan Chi","family":"Vo","sequence":"first","affiliation":[{"name":"Emory University School of Medicine","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Snyder","sequence":"additional","affiliation":[{"name":"University Hospitals Rainbow Babies and Children's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"McCracken","sequence":"additional","affiliation":[{"name":"Children's Hospital of Atlanta & Emory University School of Medicine","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"McCracken","sequence":"additional","affiliation":[{"name":"University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Aman","sequence":"additional","affiliation":[{"name":"Ohio State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Tierney","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Eugene","family":"Arnold","sequence":"additional","affiliation":[{"name":"Ohio State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levi","sequence":"additional","affiliation":[{"name":"University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kelleman","sequence":"additional","affiliation":[{"name":"Children's Hospital of Atlanta & Emory University School of Medicine","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Carroll","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Morrissey","sequence":"additional","affiliation":[{"name":"University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Vitiello","sequence":"additional","affiliation":[{"name":"National Institute of Mental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Scahill","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0151"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0005"},{"key":"e_1_3_3_4_1","first-page":"485","article-title":"The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects","volume":"89","author":"Aman MG","year":"1985","unstructured":"Aman MG, , Singh NN, , Stewart AW, , Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic, 89:485\u2013491, 1985.","journal-title":"Am J Ment Defic"},{"key":"e_1_3_3_5_1","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 4th ed. Text Revision. Washington DC: American Psychiatric Association; 2000."},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3150"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000145372.61239.bb"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-4222(01)00091-9"},{"issue":"4","key":"e_1_3_3_9_1","first-page":"12","article-title":"Movement disorders associated with atypical antipsychotic drugs","volume":"63","author":"Caroff SN","year":"2002","unstructured":"Caroff SN, , Mann SC, , Campbell EC, , Sullivan KA: Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry, 63 (Suppl 4):12\u201319, 2002.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7141.2008.00016.x"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0117"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/aur.239"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2013-0193"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2013.10.020"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318283983f"},{"key":"e_1_3_3_18_1","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). Rockville MD US Department of Health Education and Welfare Public Health Service Alcohol Drug Abuse and Mental Health Administration NIMH Psychopharmacology Research Branch Division of Extra-mural Research Programs 1976 pp. 534\u2013537."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40474-014-0033-3"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2006.00347.x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2014.10.002"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.726984"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.10453"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02172145"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-006-0573-0"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3782"},{"key":"e_1_3_3_28_1","first-page":"243","article-title":"Investigating drug-induced QT and QTc prolongation in the clinic: A review of statistical design and analysis considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team","volume":"39","author":"Pharmaceutical Research and Manufacturers of America QT Statistics Expert Working Team","year":"2005","unstructured":"Pharmaceutical Research and Manufacturers of America QT Statistics Expert Working Team, Patterson SD: Investigating drug-induced QT and QTc prolongation in the clinic: A review of statistical design and analysis considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. Ther Innov Regul Sci, 39:243\u2013265, 2005.","journal-title":"Ther Innov Regul Sci"},{"key":"e_1_3_3_29_1","first-page":"314","article-title":"A double-blind, placebo-controlled trial of risperidone in children with autistic disorder","volume":"347","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2002","unstructured":"Research Units on Pediatric Psychopharmacology Autism Network: A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. N Engl J Med, 347:314\u2013321, 2002.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1361"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.11.1266"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00427.x"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2016.02.016"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15010055"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.863209"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2005.03.023"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2003-0264-F"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300327"},{"key":"e_1_3_3_39_1","unstructured":"Sparrow SS Balla DA Cicchetti DV: Vineland Adaptive Behavior Scales. Circle Pines (Minnesota) American Guidance Service 1984."},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Townsend C Brown BS: Predicting Drug-Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures. Hoboken (New Jersey) John Wiley & Sons Inc. 2013.","DOI":"10.1002\/0471141755.ph1016s61"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.561"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3192-8"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2016.0090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2016.0090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2016.0090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:42:32Z","timestamp":1779694952000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2016.0090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1089\/cap.2016.0090"],"URL":"https:\/\/doi.org\/10.1089\/cap.2016.0090","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}